1. Thailand Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Bangkok Genomics Innovation Public Company Limited

Bangkok Genomics Innovation Public Company Limited

2.38
THB
+0.06
(+2.59%)
0.11EPS
17.97P/E
1.22BMarket Cap
Nov 11Next Earn
Bangkok Genomics Innovation Public Company Limited
SET:BKGI
(Stock Exchange of Thailand)

Recent

price

2.38

P/E

ratio

17.97

div

yld

0.00%

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
THB
- -
0.3
0.86
0.69
0.41
0.6
0.63
0.76
Revenue per Share
- -
0.03
0.24
0.17
0.05
0.09
0.08
0.11
Basic EPS, GAAP
- -
0.02
0.1
0.12
0.11
-0.04
-0.21
-0.16
Free Cash Flow per Basic Share
- -
- -
- -
0.38
0.07
- -
0.05
- -
Dividend per Share
0.05
0.07
0.25
0.41
0.39
0.9
0.92
0.97
Book Value per Share
0.05
0.07
0.25
0.41
0.39
0.89
0.88
0.93
Tangible Book Value per Share
160
440
440
440
600
567
600
600
Basic Weighted Avg Shares
- -
134
379
305
245
338
380
456
Sales/Revenue/Turnover
- -
10.58
28.12
26.16
13.69
15.54
13.07
16.26
Operating Margin (%)
- -
8
8
15
16
18
22
23
Depreciation Expense
- -
14
106
75
32
50
45
68
Net Income, GAAP
- -
- -
0.25
4.51
- -
1.69
5.28
6.28
Effective Tax Rate (%)
- -
10.32
27.86
24.65
13.1
14.86
11.95
14.93
Profit Margin (%)
-2
4
108
186
177
469
454
468
Working Capital
13
11
8
27
19
20
17
14
LT Debt
32
44
149
248
236
539
553
587
Total Equity
- -
- -
100.95
34.53
- -
12.95
8.62
12.33
Return on Invested Capital (%)
- -
- -
98.17
34.67
- -
12.52
8.22
11.82
Return on Capital (%)
- -
36.7
109.55
37.85
13.3
12.98
8.33
12.07
Return on Common Equity (%)

Capital Structure

THB

•

in mil. unless spec.
Sep'25
Dec'25
Jun'26
ST Debt
5
5
5
LT Borrowings
- -
- -
- -
LT Finance Leases
18
17
14
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
600
600
600
Market Capitalization
948
750
1,224

Working Capital

THB

•

in mil. unless spec.
Sep'25
Dec'25
Jun'26
Total Current Assets
513
580
603
Cash, Cash Equivalents & STI
338
222
233
Accounts Receivable, Net
94
139
112
Inventories
27
36
79
Total Current Liabilities
78
127
135
Payables & Accruals
68
108
118
ST Debt
5
5
5
Deferred Revenue
5
13
12

Growth Rates

THB

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
86.87%
2.6%
Free Cash Flow
- -
132.83%
448.07%
Net Income, GAAP
- -
125.19%
-9.61%
Sales/Revenue/Turnover
- -
38.87%
12.42%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
68
86
88
96
338
2025
79
70
89
142
380
2026
- -
155
- -
- -
- -

Quarterly Earnings Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.02
0.02
0.09
2025
0.01
0.01
0.01
0.04
0.08
2026
- -
0.05
- -
- -
- -

Quarterly Dividends Per Share

THB

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.05
2026
- -
- -
- -
- -
- -
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Bangkok Genomics Innovation Public Company Limited (BKGI.BK), founded in 2017 and headquartered in Bangkok, Thailand, operates as a subsidiary of BGI Genomics and provides medical laboratory testing and genomic analysis services primarily in Thailand. The company offers reproductive health screening including non-invasive prenatal testing (NIPT) for fetal chromosomal abnormalities under the NIFTY brand, preimplantation genetic testing (PGT-A) and thalassemia carrier screening under the VISTA brand, infectious disease testing such as COVID-19, monkeypox, HPV and SARS-CoV-2 serology, cancer-related genetic screening including hereditary cancer risk (SENTIS HDC) and colorectal cancer under COLOTECH, individual genetic analysis under DNALL for personalized diet, exercise and anti-aging, newborn screening, Alzheimer's and neurodegenerative disease screening, health check-ups, tech solutions like DNA/RNA sequencing, metabolomics and proteomics, and medical products including genetic sequencers, real-time PCR kits and cell-free DNA storage tubes; it serves government entities like medical schools and health centers alongside private clinics, hospitals, laboratories and research institutes. In 2025, BKGI signed an MOU with Eisai (Thailand) for Alzheimer's screening integration on January 9, a strategic partnership with MGI Tech on April 28 to expand NGS platform access, a letter of intent with the Agricultural Research Development Agency on April 29 for agricultural innovation, an intellectual property agreement with Chulalongkorn University on May 15 for CAR-T cell therapy development, and a service contract with the Institute of Medical Research on June 27 for biological age assessment research; earlier in 2024, it executed MOUs with Bumrungrad International Hospital and BGI Shenzhen for genomic medicine advancement and with the Department of Medical Sciences for knowledge exchange.